MGTX vs RGNX
MGTX: A vertically integrated clinical-stage genetic medicines company developing locally-delivered gene therapies for ophthalmology, Parkinson's disease, and xerostomia, backed by proprietary viral vector manufacturing and riboswitch gene regulation technology. RGNX: Clinical-stage gene therapy company using proprietary NAV vectors to deliver functional genes for rare genetic and retinal disorders through partnerships with major pharma.
Side-by-side fundamentals
| Metric | MGTX | RGNX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $12.16 | $10.20 | |
| Market cap as of 2026-07-23 | $1.1B | $529M | |
| PEG as of 2026-07-23 | n/a | -0.02 | |
| Net margin as of 2026-07-23 | -151.1% | -330.2% | MGTX higher |
| Gross margin as of 2026-07-23 | +95.4% | +68.2% | MGTX higher |
| Operating margin as of 2026-07-23 | -131.9% | -292.3% | MGTX higher |
| ROE as of 2026-07-23 | -315.6% | -232.5% | RGNX higher |
| ROA as of 2026-07-23 | -55.0% | -61.0% | MGTX higher |
| Debt / equity as of 2026-07-23 | 24.92 | 8.41 | RGNX lower |
| Revenue growth (YoY) as of 2026-07-23 | +131.1% | -44.0% | MGTX higher |
| Revenue CAGR (3y) SEC XBRL | +141.0% | +14.8% | MGTX higher |
| Beta as of 2026-07-23 | 1.25 | 0.91 | |
| 1-year return as of 2026-07-22 close | +41.6% | +19.0% | MGTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.